Canada markets closed

Bristol-Myers Squibb Company (BMY)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
76.84-0.16 (-0.21%)
At close: 04:00PM EDT
76.32 -0.52 (-0.68%)
After hours: 07:53PM EDT
Sign in to post a message.
  • C
    Cured
    $SLS conversation
    This is the latest from Angelo on Ovarian Cancer Data (Keytruda $MRK + GPS)
    'I am excited to share our top-line data from our combination study of GPS with the checkpoint inhibitor pembrolizumab in patients diagnosed with WT1(+) relapsed or refractory platinum-resistant advanced metastatic ovarian cancer. With 43.1 weeks of follow-up, the median overall survival among the patients in this trial has not yet been reached and the median progression-free survival was 12 weeks. This compares favorably to 8.4 weeks for pembrolizumab alone seen in a similar platinum-resistant ovarian cancer patient population in the KEYNOTE-100 study - a 43 percent increase in the GPS combination with pembrolizumab. The disease control rate was 53.9 percent – in comparison, in the KEYNOTE-100 study, the observed disease control rate was 37.2% - a 45% increase in the GPS combination with pembrolizumab.

    In this exceedingly difficult to treat patient population with active disease, the combination of GPS and pembrolizumab seems to be effective at halting or slowing down progression. GPS has typically been utilized in the remission setting and to see such intriguing data in combination with pembrolizumab in active disease is indeed exciting. I would like to wholeheartedly thank all patients for participating in the study as well as their physicians, nurses, and study teams as well as our teams at SELLAS and Merck.'

    As a note: The median overall survival is the time — expressed in months or years — when half the patients are expected to be alive. In our case it means that after 43 weeks (around > 10 months) we still have more than 50% (in a range that goes from 51 to 100%) of the patients alive, thus the median overall survival has not been reached: good stuff...

    Its either $mrk or $BMY
  • C
    Cured
    $XBI conversation
    $bmy growing revenue: Opdivo combination w Gps $sls “Opdivo is continuing to grow sales too, and it is reasonably probable that multiple combination therapies will be tested and approved in the coming years. For example, SELLAS Life Sciences (NASDAQ:SLS) recently reported updated data from a phase 1 trial of its galinpepimut-S drug in combination with BMY's Opdivo.”
  • d
    dbtunr
    Anyone else let some go over $80? Waited years for that. Just had to let some go.
  • P
    P509$
    $SLS conversation
    $BMY is sizing up a Mesothelioma market value of $3- $4 B or $150 $200 Per share
  • T
    Tim
    CVR Holders: Good news: Judge Furman ruled (finally) that the $6.4B UMB trustee lawsuit should move forward and discovery will begin immediately.
  • C
    Cured
    $SLS conversation
    I expect a significant Upfront Money with the New $BMY partnerhsip: Gps Opdivo just more than doubled survival for mesothelioma patients. "results of this single-center trial included a median overall survival of 10.5 months from the time the earlier treatment was stopped. By comparison, patients with relapsed or refractory mesothelioma typically have an estimated overall survival of just 20-24 weeks.

    Six of the eight patients in this latest trial arrived in stage 3 or 4. The median survival time of 10.5 months is expected to improve as the trial progresses. Half of the patients were alive when results were released.
  • m
    martinezvargas
    Just saw BMY published on the daily alert watchlist at (http://market-engross.club)
  • C
    Cured
    $SLS conversation
    The median survival time of 10.5 months is expected to improve as the trial progresses. Half of the patients were alive when results were released. . results of this single-center trial included a median overall survival of 10.5 months from the time the earlier treatment was stopped. (Gps $BMY Opdivo) By comparison, patients with relapsed or refractory mesothelioma typically have an estimated overall survival of just 20-24 weeks.
  • D
    Dude
    $SLS conversation
    Gps was included as future Revenue Generator for $BMY? SlS shares are a steal. $mrk bmy bidding war.
    https://seekingalpha.com/article/4520830-bristol-myers-is-melting-up-again
  • C
    Cured
    $SLS conversation
    - Expect Upfront Money w a New $BMY partnerhsip: Gps Opdivo just more than doubled survival for mesothelioma patients.
  • C
    Cured
    $SLS conversation
    Half the patients remain - Gps + Opdivo + Yervoy will become the SOC. $1B $BMY License for these rights
    "results of this single-center trial included a median overall survival of 10.5 months from the time the earlier treatment was stopped. By comparison, patients with relapsed or refractory mesothelioma typically have an estimated overall survival of just 20-24 weeks.

    Six of the eight patients in this latest trial arrived in stage 3 or 4. The median survival time of 10.5 months is expected to improve as the trial progresses. Half of the patients were alive when results were released.
  • S
    Sunshine Design
    50 forever? Nope! She’s almost 80 now. Did not think it would get here. Happy long.
  • J
    Joe
    $SLS conversation
    end stage Mesothelioma patients after having exhausted all other treatments, survive more than twice as long with GPs Opdivo $BMY - Half the patients remain alive, the survival duration continues to grow. Imagine giving GPs with Opdivo to patients earlier? Big Pharma Is going to buy GPS for Billions. Get some while they are CHEAP.
  • E
    Eddie II
    I guess I messed up selling BMY and ABBV at their prior highs...Looking good.
  • b
    brando
    I bought because cramer calls this bristol mars
  • C
    Chris
    You can pop over 80 today. Of course you can…if only for a minute or two…
    And then to 85 quick…
  • P
    P509$
    $SLS conversation
    I could see SLS doing a huge partnership deal with $BMY for Mesothelioma Patients: Early results of this single-center trial included a median overall survival of 10.5 months from the time the earlier treatment was stopped. By comparison, patients with relapsed or refractory mesothelioma typically have an estimated overall survival of just 20-24 weeks.

    Six of the eight patients in this latest trial arrived in stage 3 or 4. The median survival time of 10.5 months is expected to improve as the trial progresses. Half of the patients were alive when results were released.
  • C
    Cured
    $SLS conversation
    $bmy $mrk b like
    Median Overall Survival of 45.7 Weeks for Patients Treated With Combination Therapy for at Least One Month; Median Overall Survival in Relapsed/Refractory Patients Treated with Standard of Care is 28 Weeks
  • C
    Cured
    $SLS conversation
    $bmy Median Overall Survival of 45.7 Weeks for Patients Treated With Combination Therapy for at Least One Month; Median Overall Survival in Relapsed/Refractory Patients Treated with Standard of Care is Approximately 28 Weeks